F:No: 7-5/2013/EU/WC-0081 Government of India Directorate General of Health Services Central Drugs Standard Control Organisation (International Cell)

FDA Bhawan, Kotla Road New Delhi-110002 Dated: 0 5 JUL 2019

To M/s. Alembic Pharmaceuticals Limited, (API Division Panelav) at-Panelav, Tal-Halol, Dist-Panchmahal, Gujarat, India

SUB: Written Confirmation of M/s. Alembic Pharmaceuticals Limited, (API Division Panelav) at-Panelav, Tal-Halol, Dist-Panchmahal, Gujarat, India as per requirement of EU for import of active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India-reg.

Sir,

Please refer to your application submitted to CDSCO, Ahmedabad Zone and the recommendation received from DDC (I), Ahmedabd on the above noted subject.

Written Confirmation as required for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India is herewith granted subject to the following conditions:-

- 1. The Active Pharmaceutical Ingredients shall confirm to Good Manufacturing Practices mentioned in the EU directives or other equivalent (GMP of WHO/ICH Q7).
- 2. The manufacturer is subject to regular, strict and transparent controls and to the effective enforcement of Good Manufacturing Practice, including repeated and unannounced inspections, so as to ensure a protection of public health equivalent to that in the EU.
- The manufacturer is required to follow the Guidance document for Issue of Written Confirmation as issued by CDSCO.
- 4. Written Confirmation shall be produced by the Authorized Exporter as and when required by the Drug Regulatory Authority.
- 5. The Written Confirmation will be withdrawn in the events of non-compliance of Standards.
- 6. This Written Confirmation, unless it is sooner suspended or cancelled, shall be valid for a period of three years.

%

- 7. In the event of any Non-Compliance observed during inspections conducted by Local or International Drug Authorities, the same shall be forwarded to this office within 7 days of receipt of report.
- 8. In the event of any drug found not of standard quality, the same shall be reported to this office within 7 days of receipt of report.

Please note that Written Confirmation issued is liable to be suspended / cancelled, if any of the conditions stipulated above are not complied with or in case of violation of the provisions of the Drugs & Cosmetics Act, 1940 and the Rules thereunder as the case may be.

Please acknowledge the receipt.

Annexure No.	No. of Products	Date of Issue	Valid upto
01	39	05 JUL 2019	02.07.2022
02	06	05 JUL 2019	02.072022

Yours faithfully,

(Dr. S. Eswara Reddy) Drugs Controller General (India)

27.06.2019 27.06.2019



MINISTRY OF HEALTH & FAMILY WELFARE Central Drugs Standard Control Organization

CERTIFICATE NO.:

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site: M/s. Alembic Pharmaceuticals Limited, (API Division Panelav), at-Panelav, Tal-Halol, Dist-Panchmahal, Gujarat, India

2. Manufacturer's license Number: G/1411 & G/1050

Regarding the manufacturing plant under (1) of the following Active substance(s) exported to the EU for medicinal products for human use

As per list Annexed

The issuing Regulatory Authority hereby confirms that:

The standards of good manufacturing practice applicable to this manufacturing plant are at least equivalent to those laid down in the EU (= GMP of WHO/ICH Q7):

The manufacturing plant is subject to regular, strict and transparent controls and to the effective enforcement of good manufacturing practice, including repeated and unannounced inspections, so as to ensure a protection of public health at least equivalent to that in the EU; and

In the event of findings relating to non-compliance, information on such findings is supplied by the exporting third country without delay to the EU.

Date of Inspection of the plant: 20th & 21st JUN 2018 &12 JUL 2018

The Written Confirmation remains valid until: 02.07.2022

The authenticity of this written confirmation may be verified with the issuing regulatory authority.

This written confirmation is without prejudice to the responsibilities of the manufacturer to the quality of the medicinal product in accordance with Directive 2001/83/EC.

Address of the issuing regulatory authority: Central Drugs Standard Control Organisation

FDA Bhawan, Kotla Road, New Delhi- 110 002,India.

Name and function of responsible person: Dr.S.Eswara Reddy.

Drugs Controller General (India).

E-mail:

Telephone no.:

Fax no.:

dci@nic.in,

+91-11-23236965

+91-11-23236973

Signature

Stamp of the authority and date

05 JUI 2019

27.06.2019

Propositional

Annexure- 01 WC 0081

CERTIFICATE NO.:

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

SI.No	Name of the Active substances			
28	I dillipexole Dinydrochlorida Manual	Activitie(S)		
29	Pregabalin Ph.Eur			
30	Quetiapine Fumarate Ph.Eur	Manufacturing & Packing		
31	Rivastigmine Base Ph.Eur	Manufacturing & Packing		
32	Rivastigmine Hydrogen Tartrate EP	Manufacturing & Packing		
33	Rivastigmine Tartrate LISD	Manufacturing & Packing		
34	Ropinirole Hydrochloride USP	Manufacturing & Packing		
35	Roxithromycin Ph.Eur	ivianufacturing & Packing		
36	Telmisartan EP	Manufacturing & Packing		
37	Valsartan Ph.Eur	Manufacturing & Packing		
38	Venlafaxine Hydrochloride Ph.Eur	Manufacturing & Packing		
39	Vildagliptin	Manufacturing & Packing		
Manufacturing & Packing				

ITEM(S) Thirty Nine (39) Only

The Written Confirmation remains valid until: 02.07.2022

Signature

Stamp of the authority and date

05 JUL 2019

\$27.06.2019

Pg: 2 of 2

Annexure- 01 WC 0081

CERTIFICATE NO.:

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site: M/s. Alembic Pharmaceuticals Limited,
(API Division Panelav) at -Panelav,
Tal-Halol, Dist-Panchmahal,
Gujarat, INDIA.

List of APIs:-

SI.No	Name of the Active substances	Activitie(s)
1.	Azithromycin Dihydrate EP	Manufacturing & Packing
2.	Azithromycin Monohydrate EP	Manufacturing & Packing
3.	Bupropion Hydrochloride USP	Manufacturing & Packing
4.	Celecoxib EP	Manufacturing & Packing
5.	Clarithromycin EP	Manufacturing & Packing Manufacturing & Packing
6.	Clonidine Hydrochloride Ph.Eur/USP	Manufacturing & Packing
7.	Clonidine USP	Manufacturing & Packing
8.	Deferasirox IH	Manufacturing & Packing
9.	Erythromycin EP	Manufacturing & Packing
10		Manufacturing & Packing
11.		Manufacturing & Packing
12.		Manufacturing & Packing
	Fluoxetine Hydrochloride EP	Manufacturing & Packing
14.		Manufacturing & Packing
15.	Irbesartan Ph.Eur	Manufacturing & Packing
16.	11.201	Manufacturing & Packing
17.	The state of the s	Manufacturing & Packing
		Manufacturing & Packing
19.	Lamotrigine Ph.Eur	Manufacturing & Packing
		Manufacturing & Packing
20.	The state of the s	Manufacturing & Packing
21.		Manufacturing & Packing
22.	Memantine Hydrochloride IH	Manufacturing & Packing
23.	Metoprolol Succinate USP	Manufacturing & Packing
24.	Metoprolol Tartrate USP	Manufacturing & Packing
25.	, and a strict in the strict i	Manufacturing & Packing
26.	Modafinil Ph.Eur	Manufacturing & Packing
27.	Olmesartan Medoxomil Ph.Eur	Manufacturing & Packing

% Dtg

19 010 Ald

Pg: 1 of 2



Annexure – 02 WC-081

CERTIFICATE NO.:

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site: M/s. Alembic Pharmaceuticals Limited, (API Division Panelav), at-Panelav, Tal-Halol, Dist-Panchmahal, Gujarat, India

List of APIs:

S. No.	Name of the Active substance(s)	
1	Fenofibric Acid Choline Salt IH	Activity(ies)
2	Fenofibric Acid IH	Manufacturing & Packing.
3		Manufacturing & Packing.
3	O-Desmethyl Venlafaxine Succinate Monohydrate IH	Manufacturing & Packing.
4	Menrohamata LICD	
5		Manufacturing & Packing.
6	Teriflunomido III	Manufacturing & Packing.
	ITEM(S) S: (SS)	Manufacturing & Packing.

ITEM(S) Six (06) Only

This certificate is being issued subject to condition that the firm shall obtain NOC from the Competent Authority, on case to case basis, to manufacture the above mentioned active substances for the purpose of export only, as the above mentioned active substances are not approved for manufacture or sale in India.

The Written Confirmation remains valid until: 02.07.2022

Signature

Stamp of the authority and date

05 JUL 2019

16 x 206.2019

2010 Pollogles